Security key
055477103
Bicara Therapeutics Inc. - COMMON STOCK (BCAX)
CUSIP: 055477103
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 49,994,786
- Total 13F value
- $789,088,187
- Share change
- -1,056,866
- SEC-reported price per share
- $15.79
- Number of holders
- 112
- Value change
- +$2,780,392
- Number of buys
- 63
- Number of sells
- 43
- Shares outstanding
- 66,780,286
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
112
Top holders
10
BCAX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Bicara Therapeutics Inc. SEC filings
Bicara Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 055477103
Recent filing periods:
Ownership snapshot
Top reported holders of BCAX - Bicara Therapeutics Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Invus Global Management, LLC
Disclosed value leader
Biocon Ltd
Comparable rows
1/15
Latest evidence
30 Jun 2025
13D/G
3/4/5
13F
Lead comparable stake: 9.6%
14 rows are not safely comparable across share classes.
13D/G row: Invus Global Management, LLC
Showing 1-6 of 15 holder rows.
Quick read
Invus Global Management, LLC leads the comparable SEC ownership view at 9.6%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Invus Global Management, LLC's linked filing trail.
Comparable ownership
Top 1
Invus Global Management, LLC
9.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
9.6%
Reported 13D/G
· 30 Jun 2025
|
$50,656,769
5,216,969 shares
|
$0 | 30 Jun 2025 |
| Biocon Ltd |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$73,155,178
5,523,897 shares
|
— | 16 Sep 2024 |
| TPG GP A, LLC |
13F
3/4/5
Company · Former 10% Owner
|
—
denominator unverified
|
$27,966,848
3,010,425 shares
|
— | 30 Jun 2025 |
| James E. Flynn |
3/4/5
Possible Members of 10% Group, 10%+ Owner
|
—
denominator unverified
|
$23,774,208
1,795,174 shares
|
— | 17 Sep 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
denominator unverified
|
$64,621,175
6,955,993 shares
|
— | 30 Jun 2025 |
| Siren, L.L.C. |
13F
Individual
|
—
denominator unverified
|
$48,465,642
5,216,969 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
112
Shares
49,994,786
Rows available
112
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
105
Q3 2025 holders
112
Holder diff
7
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend